Collaborative efforts driving progress in pediatric acute myeloid leukemia

C. Michel Zwaan, Edward A. Kolb, Dirk Reinhardt, Jonas Abrahamsson, Souichi Adachi, Richard Aplenc, Eveline S J M De Bont, Barbara De Moerloose, Michael Dworzak, Brenda E S Gibson, Henrik Hasle, Guy Leverger, Franco Locatelli, Christine Ragu, Raul C. Ribeiro, Carmelo Rizzari, Jeffrey E. Rubnitz, Owen P. Smith, Lillian Sung, Daisuke Tomizawa & 3 others Marry M. Van Den Heuvel-Eibrink, Ursula Creutzig, Gertjan J L Kaspers

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid leukemia (AML) have made enormous progress during the past decades. Because AML is a rare type of childhood cancer, with an incidence of approximately seven occurrences per 1 million children annually, national and international collaborative efforts have evolved. This overview describes these efforts and includes a summary of the history and contributions of each of the main collaborative pediatric AML groups worldwide. The focus is on translational and clinical research, which includes past, current, and future clinical trials. Separate sections concern acute promyelocytic leukemia, myeloid leukemia of Down syndrome, and relapsed AML. A plethora of novel antileukemic agents that have emerged, including new classes of drugs, are summarized as well. Finally, an important aspect of the treatment of pediatric AML - supportive care - and late effects are discussed. The future is bright, with a wide range of emerging innovative therapies and with more and more international collaboration that ultimately aim to cure all children with AML, with fewer adverse effects and without late effects.

Original languageEnglish
Pages (from-to)2949-2962
Number of pages14
JournalJournal of Clinical Oncology
Volume33
Issue number27
DOIs
Publication statusPublished - Sep 20 2015

Fingerprint

Acute Myeloid Leukemia
Pediatrics
Acute Promyelocytic Leukemia
Investigational Therapies
Myeloid Leukemia
Translational Medical Research
Down Syndrome
History
Clinical Trials
Incidence
Therapeutics
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Zwaan, C. M., Kolb, E. A., Reinhardt, D., Abrahamsson, J., Adachi, S., Aplenc, R., ... Kaspers, G. J. L. (2015). Collaborative efforts driving progress in pediatric acute myeloid leukemia. Journal of Clinical Oncology, 33(27), 2949-2962. https://doi.org/10.1200/JCO.2015.62.8289

Collaborative efforts driving progress in pediatric acute myeloid leukemia. / Zwaan, C. Michel; Kolb, Edward A.; Reinhardt, Dirk; Abrahamsson, Jonas; Adachi, Souichi; Aplenc, Richard; De Bont, Eveline S J M; De Moerloose, Barbara; Dworzak, Michael; Gibson, Brenda E S; Hasle, Henrik; Leverger, Guy; Locatelli, Franco; Ragu, Christine; Ribeiro, Raul C.; Rizzari, Carmelo; Rubnitz, Jeffrey E.; Smith, Owen P.; Sung, Lillian; Tomizawa, Daisuke; Van Den Heuvel-Eibrink, Marry M.; Creutzig, Ursula; Kaspers, Gertjan J L.

In: Journal of Clinical Oncology, Vol. 33, No. 27, 20.09.2015, p. 2949-2962.

Research output: Contribution to journalArticle

Zwaan, CM, Kolb, EA, Reinhardt, D, Abrahamsson, J, Adachi, S, Aplenc, R, De Bont, ESJM, De Moerloose, B, Dworzak, M, Gibson, BES, Hasle, H, Leverger, G, Locatelli, F, Ragu, C, Ribeiro, RC, Rizzari, C, Rubnitz, JE, Smith, OP, Sung, L, Tomizawa, D, Van Den Heuvel-Eibrink, MM, Creutzig, U & Kaspers, GJL 2015, 'Collaborative efforts driving progress in pediatric acute myeloid leukemia', Journal of Clinical Oncology, vol. 33, no. 27, pp. 2949-2962. https://doi.org/10.1200/JCO.2015.62.8289
Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. Journal of Clinical Oncology. 2015 Sep 20;33(27):2949-2962. https://doi.org/10.1200/JCO.2015.62.8289
Zwaan, C. Michel ; Kolb, Edward A. ; Reinhardt, Dirk ; Abrahamsson, Jonas ; Adachi, Souichi ; Aplenc, Richard ; De Bont, Eveline S J M ; De Moerloose, Barbara ; Dworzak, Michael ; Gibson, Brenda E S ; Hasle, Henrik ; Leverger, Guy ; Locatelli, Franco ; Ragu, Christine ; Ribeiro, Raul C. ; Rizzari, Carmelo ; Rubnitz, Jeffrey E. ; Smith, Owen P. ; Sung, Lillian ; Tomizawa, Daisuke ; Van Den Heuvel-Eibrink, Marry M. ; Creutzig, Ursula ; Kaspers, Gertjan J L. / Collaborative efforts driving progress in pediatric acute myeloid leukemia. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 27. pp. 2949-2962.
@article{a2bfee5bac4f4e70903fd87a3ad39406,
title = "Collaborative efforts driving progress in pediatric acute myeloid leukemia",
abstract = "Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid leukemia (AML) have made enormous progress during the past decades. Because AML is a rare type of childhood cancer, with an incidence of approximately seven occurrences per 1 million children annually, national and international collaborative efforts have evolved. This overview describes these efforts and includes a summary of the history and contributions of each of the main collaborative pediatric AML groups worldwide. The focus is on translational and clinical research, which includes past, current, and future clinical trials. Separate sections concern acute promyelocytic leukemia, myeloid leukemia of Down syndrome, and relapsed AML. A plethora of novel antileukemic agents that have emerged, including new classes of drugs, are summarized as well. Finally, an important aspect of the treatment of pediatric AML - supportive care - and late effects are discussed. The future is bright, with a wide range of emerging innovative therapies and with more and more international collaboration that ultimately aim to cure all children with AML, with fewer adverse effects and without late effects.",
author = "Zwaan, {C. Michel} and Kolb, {Edward A.} and Dirk Reinhardt and Jonas Abrahamsson and Souichi Adachi and Richard Aplenc and {De Bont}, {Eveline S J M} and {De Moerloose}, Barbara and Michael Dworzak and Gibson, {Brenda E S} and Henrik Hasle and Guy Leverger and Franco Locatelli and Christine Ragu and Ribeiro, {Raul C.} and Carmelo Rizzari and Rubnitz, {Jeffrey E.} and Smith, {Owen P.} and Lillian Sung and Daisuke Tomizawa and {Van Den Heuvel-Eibrink}, {Marry M.} and Ursula Creutzig and Kaspers, {Gertjan J L}",
year = "2015",
month = "9",
day = "20",
doi = "10.1200/JCO.2015.62.8289",
language = "English",
volume = "33",
pages = "2949--2962",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "27",

}

TY - JOUR

T1 - Collaborative efforts driving progress in pediatric acute myeloid leukemia

AU - Zwaan, C. Michel

AU - Kolb, Edward A.

AU - Reinhardt, Dirk

AU - Abrahamsson, Jonas

AU - Adachi, Souichi

AU - Aplenc, Richard

AU - De Bont, Eveline S J M

AU - De Moerloose, Barbara

AU - Dworzak, Michael

AU - Gibson, Brenda E S

AU - Hasle, Henrik

AU - Leverger, Guy

AU - Locatelli, Franco

AU - Ragu, Christine

AU - Ribeiro, Raul C.

AU - Rizzari, Carmelo

AU - Rubnitz, Jeffrey E.

AU - Smith, Owen P.

AU - Sung, Lillian

AU - Tomizawa, Daisuke

AU - Van Den Heuvel-Eibrink, Marry M.

AU - Creutzig, Ursula

AU - Kaspers, Gertjan J L

PY - 2015/9/20

Y1 - 2015/9/20

N2 - Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid leukemia (AML) have made enormous progress during the past decades. Because AML is a rare type of childhood cancer, with an incidence of approximately seven occurrences per 1 million children annually, national and international collaborative efforts have evolved. This overview describes these efforts and includes a summary of the history and contributions of each of the main collaborative pediatric AML groups worldwide. The focus is on translational and clinical research, which includes past, current, and future clinical trials. Separate sections concern acute promyelocytic leukemia, myeloid leukemia of Down syndrome, and relapsed AML. A plethora of novel antileukemic agents that have emerged, including new classes of drugs, are summarized as well. Finally, an important aspect of the treatment of pediatric AML - supportive care - and late effects are discussed. The future is bright, with a wide range of emerging innovative therapies and with more and more international collaboration that ultimately aim to cure all children with AML, with fewer adverse effects and without late effects.

AB - Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid leukemia (AML) have made enormous progress during the past decades. Because AML is a rare type of childhood cancer, with an incidence of approximately seven occurrences per 1 million children annually, national and international collaborative efforts have evolved. This overview describes these efforts and includes a summary of the history and contributions of each of the main collaborative pediatric AML groups worldwide. The focus is on translational and clinical research, which includes past, current, and future clinical trials. Separate sections concern acute promyelocytic leukemia, myeloid leukemia of Down syndrome, and relapsed AML. A plethora of novel antileukemic agents that have emerged, including new classes of drugs, are summarized as well. Finally, an important aspect of the treatment of pediatric AML - supportive care - and late effects are discussed. The future is bright, with a wide range of emerging innovative therapies and with more and more international collaboration that ultimately aim to cure all children with AML, with fewer adverse effects and without late effects.

UR - http://www.scopus.com/inward/record.url?scp=84942279743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942279743&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.62.8289

DO - 10.1200/JCO.2015.62.8289

M3 - Article

VL - 33

SP - 2949

EP - 2962

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 27

ER -